Related Experiment Video
Updated: May 7, 2026
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Melanoma mutagenesis and aberrant cell signaling
Danielle M Bello1, Charlotte E Ariyan, Richard D Carvajal
1Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. carvajar@mskcc.org.
Cancer Control : Journal of the Moffitt Cancer Center
|October 1, 2013
Summary
Targeted therapies are emerging for malignant melanoma, a fatal skin cancer. Understanding gene mutations in pathways like MAPK and PI3K is key to developing more effective treatments for melanoma patients.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Malignant melanoma is the deadliest skin cancer.
- Traditional classification relies on histology and location.
- Melanoma is increasingly recognized as a group of molecularly distinct diseases.
Purpose of the Study:
- To review signaling pathways in melanoma.
- To describe the role of gene mutations (BRAF, NRAS, KIT, GNAQ, GNA11) in melanoma.
- To highlight opportunities for targeted therapy.
Main Methods:
- Review of scientific literature on melanoma signaling pathways.
- Analysis of gene mutations and their impact on cellular signaling.
- Examination of targeted therapies for specific melanoma subtypes.
Main Results:
- Mutations in MAPK and PI3K pathways are common in melanoma.
- BRAF V600E mutations confer sensitivity to RAF and MAPK/ERK inhibitors.
- KIT, GNAQ, and GNA11 mutations are associated with specific melanoma types and potential therapeutic targets.
Conclusions:
- Molecular understanding has advanced melanoma treatment.
- Continued research into mutations and targets is crucial for developing better therapies.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...